INTRALIPID 30% 250mL injection bag Australia - English - Department of Health (Therapeutic Goods Administration)

intralipid 30% 250ml injection bag

fresenius kabi australia pty ltd - soya oil, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: glycerol; egg lecithin; sodium hydroxide; water for injections - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake. intralipid 30% is particularly suitable for patients on fluid restriction due to its more concentrated form. this also provides an advantage in patients with a high energy requirement. a lower phospholipid/triglyceride ratio provides less phospholipids than the same amount of energy from intralipid 200mg/l. about 60% of the fatty acids in intralipid are essential fatty acids.

INTRALIPID 20% 500mL injection bag Australia - English - Department of Health (Therapeutic Goods Administration)

intralipid 20% 500ml injection bag

fresenius kabi australia pty ltd - soya oil, quantity: 200 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; egg lecithin; glycerol; water for injections - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

INTRALIPID 20% 100mL injection bag Australia - English - Department of Health (Therapeutic Goods Administration)

intralipid 20% 100ml injection bag

fresenius kabi australia pty ltd - soya oil, quantity: 200 g/l - injection, intravenous infusion - excipient ingredients: glycerol; sodium hydroxide; water for injections; egg lecithin - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

INTRALIPID 10% 50g/500mL injection bag Australia - English - Department of Health (Therapeutic Goods Administration)

intralipid 10% 50g/500ml injection bag

fresenius kabi australia pty ltd - soya oil, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: water for injections; glycerol; egg lecithin; sodium hydroxide - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Intralipid New Zealand - English - Medsafe (Medicines Safety Authority)

intralipid

fresenius kabi new zealand limited - soya oil 10%{relative};  ;   - solution for infusion - 10 % - active: soya oil 10%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Intralipid New Zealand - English - Medsafe (Medicines Safety Authority)

intralipid

fresenius kabi new zealand limited - soya oil 20%{relative};  ;   - solution for infusion - 20 % - active: soya oil 20%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Intralipid New Zealand - English - Medsafe (Medicines Safety Authority)

intralipid

fresenius kabi new zealand limited - soya oil 30%{relative};  ;   - solution for infusion - 30 % - active: soya oil 30%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

AMINOVEN amino acid 10% solution for infusion 1000 mL bottle Australia - English - Department of Health (Therapeutic Goods Administration)

aminoven amino acid 10% solution for infusion 1000 ml bottle

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

AMINOVEN amino acid 10% solution for infusion 500 mL bottle Australia - English - Department of Health (Therapeutic Goods Administration)

aminoven amino acid 10% solution for infusion 500 ml bottle

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

VITALIPID N INFANT INJECTION Singapore - English - HSA (Health Sciences Authority)

vitalipid n infant injection

fresenius kabi (singapore) pte ltd - vitamin a; vitamin d2; vitamin e; vitamin k1 - injection - 230 iu/ml - vitamin a 230 iu/ml; vitamin d2 40 iu/ml; vitamin e 0.7 iu/ml; vitamin k1 20 mcg/ml